TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Description: Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (\~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
Study: NCT06065566

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention.
Study: NCT04000152

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: niPGT-A
Description: Two scenarios should be considered according to the results in the SBM analysis:~1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).~2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.~In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morphology criteria
Description: Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
Study: NCT00736307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured limbal stem cells Transplantation
Description: Transplantation of cultivated limbal epithelium on amniotic membrane
Study: NCT03253549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMArTVIEW
Description: Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
Study: NCT01741766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Training
Description: The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
Study: NCT00443079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdB 1016 (Siliphos)
Description: 1 pill 3 times daily x 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdB 1016 (Siliphos)
Description: 1 pill 3 times daily x 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched placebo
Description: 1 pill 3 times daily x 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched placebo
Description: 1 pill 3 times daily x 6 weeks
Study: NCT03660774

Intervention type: OTHER
Intervention: No treatment given
Description: The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
Study: NCT03798509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19 targeted T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study: NCT01522001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care model
Description: * First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge.
Study: NCT04663451

Intervention type: RADIATION
Intervention: radioacive iodine therapy
Description: Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.

Intervention type: RADIATION
Intervention: radioacive iodine therapy
Description: Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
Study: NCT00967382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin sodium
Description: Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum
Study: NCT02218879

Intervention type: DRUG
Intervention: Tecfidera
Description: Oral Tecfidera 240 mg bid
Study: NCT00308256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-counselling
Description: Phone calls performed by nurse 15 days after each monthly visit
Study: NCT02841176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermography
Description: Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
Study: NCT02442570

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human alpha B-crystallin
Description: intravenous injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: intravenous injection
Study: NCT03743805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: 0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
Study: NCT03255161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community health worker-audiologist communication education and support group
Description: A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
Study: NCT04155216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation and guided imagery program
Description: Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
Study: NCT02464774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy
Description: Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy
Description: Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
Study: NCT04617132

Intervention type: BEHAVIORAL
Intervention: MBCT/MBSR
Description: This intervention teaches the practice of mindfulness - being aware of the present moment without judgement - to help reduce the emotional reactivity to thoughts and bodily sensations, which prevents downward spirals into depression, anxiety, or fear.
Study: NCT02573922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone-naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study: NCT03591367

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MicroRNAs-155
Description: Quantitative analysis of cell-free miR-155 using RT-qPCR.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Human telomerase reverse transcriptase
Description: Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
Study: NCT02296190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
Study: NCT02178566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Treprostinil
Description: A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Treprostinil
Description: A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
Study: NCT01857401

Intervention type: OTHER
Intervention: No intervention, observational study only
Description: No intervention. We are collecting blood for an ex vivo study
Study: NCT04589533

Intervention type: OTHER
Intervention: educational program
Description: The educational program will be based on: a outreach visit (a 3-h face-to-face meeting between a trained diabetes specialist from outside the Center and the staff of the Center itself) and a distance learning (FAD).The educational programme will be focused on current Diabetes Guidelines recommendations and based on possible deviations from the best clinical practice observed during phase1
Study: NCT02081950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Description: comparison of 2 different administration of drug
Study: NCT02464774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
Study: NCT04780373

Intervention type: OTHER
Intervention: data collection
Description: clinical data collection

Intervention type: OTHER
Intervention: data collection
Description: clinical data collection
Study: NCT02464774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
Study: NCT01578473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: oral softgel 2000 IU once daily 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Pellets
Description: subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
Study: NCT04786340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
Description: WST-057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: WST-057 4mL topical solution
Description: Placebo
Study: NCT04075266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Study: NCT01016301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist service
Description: Medication Review, medication report
Study: NCT04176380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Autologous T cells
Description: Autologous rapamycin resistant Th1/Tc1 cells
Study: NCT03245138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Third Ventriculostomy
Description: patients receive an endoscopic third ventriculotomy as surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculo-Peritoneal Shunting
Description: patients receive an ventriculo-peritoneal shunt as surgical procedure
Study: NCT04182711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: Phase 1: Time taken for each patient is 25 mins Phase 2: Time taken for each patient is 30 mins
Study: NCT02009202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study: NCT04075266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Study: NCT01257113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise
Description: This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homebased exercises
Description: This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
Study: NCT03442608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zoll 2000 and/or CureWrap 3500 cooling system
Description: Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Zoll 2000 and/or CureWrap 3500 cooling system
Description: Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
Study: NCT02009202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: picosulphate
Study: NCT04658641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific: Study tool computer
Description: Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific: Study tool computer
Description: Compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
Study: NCT02282631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive scheme
Description: Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
Study: NCT03344224

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: laboratory test

Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: laboratory test
Study: NCT03504163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: Pembrolizumab (MK-3475) will be administered as a 400 mg intravenous (IV) infusion at 6- week intervals for 9 doses over a 48-week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
Study: NCT02119793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE contour
Description: YVOIRE contour injection into the anteromedial malar region
Study: NCT01223625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg/day
Description: Rosuvastatin 5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg/day
Description: Rosuvastatin 40mg/day
Study: NCT02129413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta system
Study: NCT01826578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: using only one port for laparoscopic surgery
Description: using only one port for laparoscopic surgery
Study: NCT03702335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
Study: NCT03504163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Intravesical BCG will be administrated once per week over a 6-week period as induction therapy, followed by maintenance BCG consistent with standard clinical practice
Study: NCT02460692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronabinol
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Study: NCT03460405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Vaccine
Description: 1 dose of Vi-DT Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Vaccine
Description: 1 dose of Vi-DT Vaccine
Study: NCT02460692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized Cannabis 3.7% THC/5.6% CBD
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Study: NCT03460405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT Vaccine
Description: 1 dose of Vi-DT Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide Vaccine
Description: 1 dose of Vi Polysaccharide Vaccine
Study: NCT03460028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Condition
Description: Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
Study: NCT04253327

Intervention type: OTHER
Intervention: questionnaire
Description: Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email..

Intervention type: OTHER
Intervention: questionnaire
Description: Patients will be contacted by their physician during regular follow-up in the out-patient clinic or contacted by phone.~The questionnaires will be filled in at the UZBrussel, Laarbeeklaan 101, 1090 Brussels or at the patients home.~Filled-in questionnaires can be hand off immediately at the physician or send by post or email..